Protective effects of glucagon-like peptide 2 on intestinal ischemia-reperfusion rats.
Our objective was to evaluate the protective effects of glucagon-like peptide 2 (GLP-2) on intestinal ischemia/reperfusion (I/R) rats. Thirty-two rats were randomly assigned to four experimental groups, each of 8: Group A, sham rats underwent laparotomy only, without superior mesenteric artery (SMA) occlusion; Group B, I/R animals underwent laparotomy and occlusion of the SMA for 60 minutes followed by 120 minutes of reperfusion; Group C, I/R animals underwent intestinal I/R, and received pretreatment with GLP-2 for 3 days preoperatively; and Group D, I/R animals underwent intestinal I/R, received pretreatment with GLP-2 as above, and during the reperfusion phase were injected intravenously with GLP-2. After the reperfusion of intestinal ischemia, samples of intestinal mucosa, mesenteric lymph nodes (MLN) and blood were prepared for determination. In the pretreatment rats with GLP-2 (group C), Chiu's scores, bacterial colony counts, serum D-lactate, intestinal mucosal MDA and ET-1, and serum endotoxin, TNF-alpha and IL-6 were significantly reduced compared with intestinal I/R rats (group B). Administration of GLP-2 during the reperfusion phase following pretreatment (group D) showed further protective effects in comparison with the pretreatment rats (group C). We conclude that treatment with GLP-2 attenuates intestinal I/R injury, reduces bacterial translocation, inhibits the release of oxygen free radicals and ET-1, and may well inhibit the production of proinflammatory cytokines.
Zhang
Wei
W
Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, People's Republic of China.
Zhu
Weiming
W
Zhang
Jian
J
Li
Ning
N
Li
Jieshou
J
D000818:Animals; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D019332:Endothelin-1 / Q000378:metabolism; D004731:Endotoxins / Q000097:blood; D053767:Glucagon-Like Peptide 2 / Q000008:administration & dosage / Q000494:pharmacology*; D015850:Interleukin-6 / Q000097:blood; D007413:Intestinal Mucosa / Q000098:blood supply* / Q000187:drug effects* / Q000503:physiopathology; D019194:Ischemic Preconditioning / Q000379:methods*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000503:physiopathology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D019332:Endothelin-1; D004731:Endotoxins; D053767:Glucagon-Like Peptide 2; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D008315:Malondialdehyde